A characteristic sequence of trisomies starting with trisomy 7 in benign thyroid tumors.

Hum Genet

Zentrum für Humangenetik und genetische Beratung, Universität Bremen, Germany.

Published: August 1994

The cytogenetic results from a series of 113 thyroid hyperplasias and adenomas are reported; 15 showed clonal karyotypic alterations. In addition to a group showing translocations involving 19q13, another subset of lesions characterized by polysomies can be found. Based on our own cases belonging to this subset and a review of the cases reported in the literature, we conclude that the characteristic feature of this group is a sequence that always starts with trisomy 7, but that sometimes even leads to chromosome numbers in the hypertriploid range. This subset of thyroid tumors may be an example of a more common genetic pathway in human solid tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF00202871DOI Listing

Publication Analysis

Top Keywords

thyroid tumors
8
characteristic sequence
4
sequence trisomies
4
trisomies starting
4
starting trisomy
4
trisomy benign
4
benign thyroid
4
tumors cytogenetic
4
cytogenetic series
4
series 113
4

Similar Publications

Introduction: The core objective of this study was to precisely locate metastatic lymph nodes, identify potential areas in nasopharyngeal carcinoma patients that may not require radiotherapy, and propose a hypothesis for reduced target volume radiotherapy on the basis of these findings. Ultimately, we reassessed the differences in dosimetry of organs at risk (OARs) between reduced target volume (reduced CTV2) radiotherapy and standard radiotherapy.

Methods And Materials: A total of 209 patients participated in the study.

View Article and Find Full Text PDF

This study aimed to explore the diagnostic value of the two cytology techniques, including liquid-based cytology of mammary ductal lavage fluid and nipple discharge smear cytology, in the intraductal lesions in patients with pathological nipple discharge (PND). This retrospective analysis included 119 patients with PND who underwent surgical treatment. At the same time, they all underwent fiberoptic ductoscopy (FDS), nipple discharge smear cytology and liquid-based cytology of ductal lavage fluid before surgery.

View Article and Find Full Text PDF

CAFs-released exosomal CREB1 promotes cell progression and immune evasion in thyroid cancer via the positive regulation of CCL20.

Autoimmunity

December 2025

Department of Thyroid Head and Neck Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.

Background: Exosomes derived from cancer-associated fibroblasts (CAFs) can affect tumor microenvironment (TME) of thyroid cancer (TC). The cAMP response element binding protein 1 (CREB1) acts as a transcription factor to participate in cancer development. Currently, we aimed to explore the molecular mechanism of exosome-associated CREB1 and C-C motif chemokine ligand 20 (CCL20) in TC.

View Article and Find Full Text PDF

[Hot topic: indications and contraindications for ultrasound-guided biopsy of thyroid nodules and cervical lymph nodes].

Zhonghua Nei Ke Za Zhi

February 2025

Department of Ultrasound Medicine, China-Japan Friendship Hospital, Beijing100029, China Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing100730, China National Respiratory Medicine Center, National Key Laboratory of Respiratory and Comorbidity, National Respiratory Medical Center National Clinical Research Center, Respiratory Diseases Respiratory Research Institute of Chinese Academy of Medical Sciences, Respiratory Center of China-Japan Friendship Hospital, Beijing100029, China.

View Article and Find Full Text PDF

[Thyroid secretory carcinoma: report of a case].

Zhonghua Bing Li Xue Za Zhi

February 2025

Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!